Because novel multitarget inhibitors have already been developed that can target certain tyrosine kinases and FAK simultaneously (e.g., PHM16, a novel dual FAK/FGFR2 inhibitor with potent anti-tumor and anti-angiogenic activities [49]), the simultaneous inhibition of FAK and FGFRs is a promising novel approach that should be investigated in human MPM models as well. This evidence concerns the gene PTK2 and neoplasm.